Treatment with FDA-approved tyrosine kinase and necroptosis inhibitor "Ponatinib" (by inhibition of RIPK1 and RIPK3 [58]) was found to reduce collagen deposition, troponin release, and promote cardiac function up to 3 months after pneumococcal pneumonia when used as an adjunct therapy to antibiotics in a mouse model[21]. The gene discussed is RIPK1; the disease is pneumococcal pneumonia.